Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway

Fig. 5

SFN and meso CAR-T cells act synergistically to mediate tumor regression in vivo. A H322-luc cells (5 × 105) were injected s.c. into NOD/SCID mice. Five days later, mice were divided into four groups randomly. Two groups were treated with PBS or SFN (40 mg/kg/day, i.p.). Another two groups received 5 × 106 meso CAR-T cell infusion (i.v.) combined with SFN (40 mg/kg/day) or anti-PD-1 (200 μg/mouse/3 days) injection (i.p). B, C Bioluminescence images of five representative mice in the four treatment groups are shown after adoptive therapies (B). The bioluminescence signal was measured at different time points (C). D Survival analysis was performed by using Kaplan-Meier survival curves. E–J NOD/SCID mice were injected with 5 × 105 H322-luc cells. Five days later, mice were injected (i.v.) with meso CAR-T cells only (CAR-T only), meso CAR-T cells pre-treated with SFN (SFN-CAR-T), a combination of meso CAR-T cells and SFN (40 mg/kg/day, i.p.) (CAR-T + SFN), and meso CAR-T cells combined with anti-PD-1 (200 μg/mouse/3 days, i.p.) (CAR-T + anti-PD-1). After 7 days, tumor tissues and spleens were harvested. Then, PD-1 expression and secretion of cytokines including IFN-γ and IL-2 of CD8+ meso CAR-T cells from tumor tissues (E–G) and spleens (H–J) were tested by flow cytometry. K Representative images of PD-L1 immunohistochemical staining on tumor tissues from different groups of mice model. J IHC score of PD-L1 in tumor tissues. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 ns; not significant (Student’s t test)

Back to article page